Semaglutide Cuts Cardiovascular Events in Landmark Trial.

Published Date: 12 Aug 2023

Semaglutide for weight loss (Wegovy) reduced cardiovascular events in the 17,000-person SELECT CV outcomes trial, according to top-line results, which should change how we think about the weight loss medication's positive effects on our health.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

4.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot